New drug tested on kids with Tough-to-Treat leukemia
NCT ID NCT02091245
Summary
This early-stage study is testing a new drug called KPT-330 in children and young adults whose leukemia has returned or stopped responding to standard treatments. The main goal is to find the highest safe dose and understand the side effects. Researchers will give different dose levels to small groups of participants to determine what amount can be tolerated.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Children's Healthcare of Atlanta
Atlanta, Georgia, 30322, United States
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Children's Hospital of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Seattle Children's Hospital
Seattle, Washington, 98101, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
-
UCSF
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.